Integra LifeSciences Holdings (IART)
Liquidity ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 1.17 | 1.20 | 3.39 | 4.68 | 3.45 | 2.89 | 2.78 | 3.65 | 3.62 | 3.93 | 3.85 | 3.38 | 3.39 | 3.32 | 3.24 | 2.52 | 3.09 | 4.52 | 4.55 | 4.09 |
| Quick ratio | 0.59 | 0.58 | 1.73 | 2.99 | 1.85 | 1.55 | 1.56 | 2.04 | 2.24 | 2.54 | 2.33 | 2.03 | 2.19 | 2.08 | 1.97 | 1.53 | 1.73 | 2.41 | 2.54 | 2.45 |
| Cash ratio | 0.30 | 0.30 | 0.90 | 2.19 | 1.01 | 0.83 | 0.87 | 1.14 | 1.42 | 1.72 | 1.53 | 1.29 | 1.51 | 1.41 | 1.25 | 0.99 | 1.17 | 1.55 | 1.70 | 1.45 |
Integra LifeSciences Holdings has demonstrated strong liquidity based on its current ratio over the years, ranging from 3.09 to 4.68. The company maintained a healthy level of current assets relative to its current liabilities during this period.
The quick ratio, which excludes inventory from current assets, also shows a favorable liquidity position for Integra LifeSciences Holdings. The quick ratio ranged from 1.53 to 2.99, indicating the company's ability to cover its short-term obligations with its most liquid assets.
Furthermore, the cash ratio for the company was relatively stable, with values ranging from 0.30 to 2.19. This indicates that Integra LifeSciences Holdings had a sufficient level of cash to cover its current liabilities during the periods analyzed.
Overall, based on these liquidity ratios, Integra LifeSciences Holdings appears to have maintained a strong liquidity position, which is essential for meeting its short-term obligations and ensuring the smooth operations of the business.
Additional liquidity measure
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 144.07 | 146.48 | 143.14 | 139.47 | 141.86 | 136.39 | 133.58 | 128.86 | 127.45 | 124.40 | 127.06 | 123.22 | 126.03 | 153.90 | 154.22 | 171.53 | 173.71 | 141.08 | 141.02 | 129.85 |
The cash conversion cycle for Integra LifeSciences Holdings has fluctuated over the period in question. Initially standing at around 130 days, it increased to around 170 days by December 31, 2020, before gradually decreasing to around 120 days by March 31, 2022. Subsequently, the cycle showed some variability but generally maintained a range between 120 to 150 days. Overall, the company's management of its cash conversion cycle indicates periods of efficiency and possible areas for improvement in working capital management. Closer monitoring and assessment may be required to ensure optimal cash flow operations in the future.